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Abstract
Background: Phosphodiesterases (PDEs) break down cAMP, thereby regulating intracellular cAMP concentrations
and diffusion. Since PDE4 predominates in airway epithelial cells, PDE4 inhibitors can stimulate Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) by increasing cAMP. Tobacco smoking and COPD are associated
with decreased CFTR function and impaired mucociliary clearance (MCC). However, the effects of the PDE4 inhibitor
roflumilast on smoke-induced mucociliary dysfunction have not been fully explored.
Methods: Primary normal human bronchial epithelial cells (NHBE) from non-smokers, cultured at the air-liquid
interface (ALI) were used for most experiments. Cultures were exposed to cigarette smoke in a Vitrocell VC-10
smoking robot. To evaluate the effect of roflumilast on intracellular cAMP concentrations, fluorescence resonance
energy transfer (FRET) between CFP- and YFP-tagged protein kinase A (PKA) subunits was recorded. Airway surface
liquid (ASL) was measured using light refraction scanning and ciliary beat frequency (CBF) employing infrared
differential interference contrast microscopy. Chloride conductance was measured in Ussing chambers and CFTR
expression was quantified with qPCR.
Results: While treatment with 100 nM roflumilast had little effect alone, it increased intracellular cAMP upon
stimulation with forskolin and albuterol in cultures exposed to cigarette smoke and in control conditions. cAMP
baselines were lower in smoke-exposed cells. Roflumilast prolonged cAMP increases in smoke-exposed and control
cultures. Smoke-induced reduction in functional, albuterol-mediated chloride conductance through CFTR was
improved by roflumilast. ASL volumes also increased in smoke-exposed cultures in the presence of roflumilast while
it did not in its absence. Cigarette smoke exposure decreased CBF, an effect rescued with roflumilast, particularly
when used together with the long-acting ß-mimetic formoterol. Roflumilast also enhanced forskolin-induced CBF
stimulation in ASL volume supplemented smoked and control cells, confirming the direct stimulatory effect of rising
cAMP on ciliary function. In active smokers, CFTR mRNA expression was increased compared to non-smokers and
ex-smokers. Roflumilast also increased CFTR mRNA levels in cigarette-smoke exposed cell cultures.
Conclusions: Our results show that roflumilast can rescue smoke-induced mucociliary dysfunction by reversing
decreased CFTR activity, augmenting ASL volume, and stimulating CBF, the latter particularly in combination with
formoterol. As expected, CFTR mRNA expression was not indicative of apical CFTR function.
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Background
The airways are continuously exposed to dust and in-
fectious agents. To prevent damage caused by irri-
tants, they require effective clearing mechanisms, the
physiologically most important one being mucociliary
clearance (MCC). Two major determinants of effect-
ive MCC are directly regulated by cAMP: Ciliary beat
frequency (CBF) [1] and the Cystic Fibrosis Trans-
membrane Conductance Regulator (CFTR), a major
anion channel regulating airway surface liquid (ASL)
volume [2].
Phosphodiesterases (PDEs) belong to a family of en-
zymes that catalyze the breakdown of the second mes-
sengers cAMP and cGMP to their inactive forms [3].
PDE4 gene products have a higher affinity to cAMP
(Km 1–10 μM) than cGMP (Km > 50 μM) and reveal a
broad tissue distribution, including the brain, gastro-
intestinal tract, spleen, lung, heart, testis and kidney [4].
The lack of effective drug therapy for chronic obstruct-
ive pulmonary disease (COPD) has increased the interest
in PDE4 inhibition in recent years [5], as PDEs are not
only highly expressed in airway epithelial cells, but also
in leukocytes and other inflammatory cells, which are in-
volved in the pathogenesis of COPD [3]. Roflumilast, a
PDE4 inhibitor with an IC50 of 0.6 nM [3], has been ap-
proved in the United States and Europe to reduce the
risk of COPD exacerbations in patients with severe
COPD associated with chronic bronchitis and a history
of exacerbations [6].
CFTR function is decreased in patients with COPD
[7, 8] and in smokers [9]. Furthermore, PDE inhibitors
have been shown to increase chloride transport through
CFTR [10]. PDE4 is one of the major isoforms expressed
in the airways [11]. These observations suggest that PDE
inhibitors could play a key role in improving MCC by
restoring depleted ASL in patients with COPD as well as
in smokers.
In this study, we examined the role of roflumilast on
parameters of MCC in normal human bronchial epithe-
lial (NHBE) cells. We found that roflumilast increased
intracellular cAMP concentrations, improved CFTR
function and enhanced CBF in cigarette smoke-exposed
NHBE cells. For some of these parameters, formoterol
had an additive effect. These results indicate that roflu-
milast rescues at least part of the dysfunctional MCC
after acute smoke exposure.
Methods
Chemicals
Roflumilast was provided by Forest Laboratories Inc.
(New York, NY, USA). All other chemicals were pur-
chased from Sigma (St. Louis, MO, USA), unless other-
wise specified.
Cell cultures
Normal human bronchial epithelial (NHBE) cells from
non-smokers were isolated from lungs unsuited for
transplant and generously donated for research by organ
donors. These lungs were recovered with IRB approved
consents by the LifeCenter Northwest in Washington
State and the Life Alliance Organ Recovery Agency of
the University of Miami. After isolation as previously de-
scribed [12–15], NHBE cells were dedifferentiated
through expansion on plastic and redifferentiated at an
air-liquid interface (ALI) on collagen-coated Transwell
permeable supports (12 mm, 24 mm and Snapwell, Co-
star Corning, Tewksbury, MA, USA). NHBE cells were
considered fully differentiated after 3–4 weeks at the
ALI as assessed by beating cilia and mucus transport.
Smoke exposure of NHBE ALI cultures
Fully differentiated NHBE cells were exposed to cigarette
smoke using a Vitrocell VC-10 smoking robot (Vitrocell
Systems GMBH, Waldkirch, Germany). Four cigarettes
(University of Kentucky 3R4F) were smoked according
to ISO standard 3308: six puffs per cigarette with a
35 mL volume per puff and a waiting time between each
puff of 60 s. Roflumilast was added 1 h before and re-
added after smoking. CBF, FRET, and CFTR conduct-
ance were measured 3 h after smoke exposure. After
these measurements, NHBE cells were lysed and lysate
stored at −20 °C for quantitative PCR.
Pseudotyped Lentivirus Vectors and Infection of Airway
Epithelial Cells
Third generation, propagation-deficient, HIV pseudo-
typed lentiviruses encoding fluorescently tagged PKA
subunits (RII-CFP and CAT-YFP) under the transcrip-
tional control of the ciliated cell-specific foxj1 promoter
were used for FRET as described previously [13]. Briefly,
recombinant lentiviruses were constructed using the
pRRLsinPPT.CMV.MCS.Wpre vector [16]. For the initial
constructs, genes encoding the catalytic PKA subunit
CAT and the regulatory PKA subunit RII, fused to the
fluorescent proteins YFP and CFP, respectively [17], were
cloned into the multiple cloning site downstream of the
ciliated cell-specific foxj1 promoter for sole expression
in ciliated cells [18]. Using calcium phosphate co-
precipitation (Clontech Laboratories, Inc., Mountain
View, CA, USA), lentiviruses were prepared by co-
transfecting HEK 293 T cells with vector and packaging
DNAs plasmids. Virus-containing medium was collected
48 h and 72 h later, concentrated by polyethylene glycol
(11 %) precipitation, and stored at −80 °C. An estimation
of the virus titer was performed using the p24 HIV Anti-
gen ELISA kit (PerkinElmer, Wellesley, MA, USA). Ded-
ifferentiated cells were used for co-infection with both
viral constructs. At the time of plating the cells on
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Transwells, virus was added at a ratio of 100 ng per
500,000 cells in bronchial epithelial growth medium
(BEGM) containing polybrene (2 μg/ml final concentra-
tion). The infection was done overnight, at 37 °C in 5 %
CO2. The following day, virus was removed, and BEGM
was changed to ALI medium top and bottom until cells
reached confluence, when an air liquid interface was cre-
ated. Expression of the fluorescently tagged proteins was
monitored using an inverted fluorescence microscope.
Measurement of CBF and FRET in airway epithelial cells
Fully differentiated NHBE cells cultured on 24 mm
Transwell supports were placed in a customized, fully
enclosed chamber, allowing independent perfusion of
the apical and basolateral compartments. The chamber
was mounted at room temperature on the stage of an
upright Nikon E600fn microscope. Water was added on
top of the closed chamber for use of a 63× water
immersion objective with a numerical aperture of 1.0.
FRET was measured as described previously [13], with
images acquired every 10s. CBF was recorded according
to published methods [13, 19], using infrared differential
interference contrast video microscopy. CBF and FRET
were measured in real time and simultaneously in cili-
ated cells that expressed both fusion proteins. In
addition, CBF was also recorded on an inverted Zeiss
Axiovert without apical perfusion before and after apical
DPBS supplementation.
Ussing chamber experiments
Snapwell filters containing fully differentiated NHBE
cells were rinsed with Krebs-Henseleit solution (KH),
and then mounted in Ussing chambers (EasyMount
Chambers; Physiologic Instruments, San Diego, CA,
USA) containing KH in apical and basolateral chambers.
Solutions were maintained at 37 °C by heated water
jackets, and were continuously bubbled with a 95 %
room air / 5 % CO2 mixture to maintain the pH at 7.4.
To monitor short-circuit current (ISC), the transepithelial
membrane potential was clamped at 0 mV with a six-
channel voltage clamp (model VCC MC6; Physiologic
Instruments) using Ag/AgCl electrodes in agar bridges.
Signals were digitized and recorded with DAQplot soft-
ware (VVI Software, College Station, PA, USA) via a
LabJack A/D converter (LabJack Corp., Lakewood, CO,
USA). The input resistance of each filter was measured
by the application of 1 mV bipolar pulses of 2-s dur-
ation. To eliminate any contribution to the Isc by epithe-
lial sodium channels, 10 μM amiloride was added to the
apical chamber. Once the Isc stabilized, roflumilast (100
nM) was included in the apical and basolateral perfusate.
After a 20 min pre-treatment with roflumilast, 10 μM
albuterol or 10 μM forskolin was added to the apical
perfusate, and the resulting increase in chloride
conductance was measured as Isc. To assure that con-
ductance changes were related to CFTR, Isc decreases
upon apical addition of 10 μM CFTRinh 172 were mea-
sured as well. To study the combination effect of long
acting ß-mimetics and roflumilast, cultures were incu-
bated with 100 nM roflumilast, 100 nM formoterol, both
or none for 2 h before exposures to smoke or air. In the
Ussing chamber, an additional 10 μM of albuterol was
added but to assess the overall influence on CFTR con-
ductance; then Isc decreases upon addition of the CFTR
inhibitor CFTRinh17 were assessed.
Airway surface liquid (ASL) volume estimates
ASL volumes from NHBE cells were estimated by me-
niscus scanning as previously described [20]. Briefly, cul-
tures were washed with phosphate buffered saline (PBS)
24 h prior to measurements to clean the filters from
mucus accumulation, which can interfere with ASL
reading. At the time of measurement, the 12 mm Trans-
well supports were placed on a commercially available
scanner (Epson perfection V500 PHOTO, Epson Amer-
ica Inc., Long Beach, CA). Scanned menisci were used to
estimate ASL volume using software generously pro-
vided by Dr. Myerburg (University of Pittsburgh). Cali-
bration of the 12 mm Transwell supports (Costar
Corning, Tewksbury, MA, USA) was done by measuring
ASL changes after apical addition of different volumes of
PBS.
Bronchoscopic sampling of airway epithelial cells
Bronchial epithelial cells from patients were obtained
during bronchoscopy under conscious sedation for other
clinical indications as approved by our IRB. After sed-
ation, a cytology brush was passed through the broncho-
scope to harvest airway epithelial cells. The brushings
were done in the left and right main bronchus just below
the carina using eight passages with ten strokes each.
After each passage, the brush was withdrawn from the
bronchoscope and rinsed in 2 ml of PBS. Cells were col-
lected from current smokers (ten pack year history of
smoking), ex-smokers (quit more than 1 year ago) and
non-smokers.
Quantitative PCR
Total RNA was isolated using the Total RNA E.Z.N.A. kit
from OMEGA (VWR International, Radnor, PA, USA).
The concentration of RNA was determined using the
NanoDrop 1000 spectrophotometer (Thermo Scientific,
Rockford, IL, USA). Complementary DNA (cDNA) was
made from total RNA using the iScript Synthesis Kit
(BioRad, Hercules, CA, USA). Messenger RNAs (mRNA)
of interest were quantified by PCR using a BioRad iCy-
cler and TaqMan probes (Life Technologies, Grand Is-
land, NY, USA). The difference in the threshold cycle
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between the targeted gene and GAPDH (ΔCt) was used
as the relative level of expression.
Statistics
Results were evaluated by one-way ANOVA. If a signifi-
cant difference was found, a parametric (Newman Keuls)
or non-parametric analysis (Dunns) using Prism 5
(GraphPad, La Jolla, CA, USA) was used for comparison
of groups. p < 0.05 was accepted as significant. Error bars
in all figures represent SEM.
Results
Effect of roflumilast on intracellular cAMP
To evaluate the effect of roflumilast on intracellular
cAMP concentration ([cAMP]i), we used our previously
described FRET assay of fluorescently tagged PKA sub-
units [13] where changes in FRET ratio (ΔFRET ratio)
are indicative of changes in [cAMP]i [13]. Apical addition
of 10 μM forskolin as well as 20 μM albuterol increased
[cAMP]i in NHBE cells. While roflumilast did not increase
cAMP when added alone, it increased the peak [cAMP]i
response to forskolin and albuterol (Fig. 1a) and prolonged
the [cAMP]i increase after forskolin washout (Fig. 1b).
Roflumilast also increased the [cAMP]i peak response
and duration to 10 μM forskolin in cultures exposed to
smoke or air (air control) in the Vitrocell VC-10 smok-
ing robot. In smoke-exposed cells, the agonist-induced
peak ΔFRET ratio response was significantly less com-
pared to the air exposed control cells in the presence of
roflumilast (Fig. 1d; each data point from three lungs with
n ≥ 21 measurements), while no difference was found for
the prolonged cAMP increase between smoke and air con-
trol (Fig. 1e). To assess the effect of cigarette smoke on
intracellular cAMP concentrations, we compared baseline
FRET ratios of smoked and air control cultures (Fig. 1c).
We found that cultures exposed to cigarette smoke had a
significantly lower baseline FRET ratio compared to air
control cultures (0.958 ± 0.023 vs 0.980 ± 0.015; 3 lungs,
n = 30, p < 0.05). While calibrations of these baselines are
not possible and these results have to take this caveat into
account, the data could indicate that acute cigarette smoke
exposure decreased intracellular cAMP concentrations. On
the other hand, it did not decrease changes in [cAMP]i re-
sponses to agonist stimulation and brought FRET ratios in
smoked cells to the baseline FRET ratios of control cells
in the absence of roflumilast. The further augmenting ef-
fect of roflumilast on peak forskolin responses, however,
Fig. 1 Effect of roflumilast on real-time [cAMP]i, estimated by FRET with and without smoke. a Treatment with 100 nM roflumilast alone (10 min)
does not increase [cAMP]i, but roflumilast enhances forskolin- and albuterol-mediated [cAMP]i increases (10 μM forskolin and 20 μM albuterol in
control cultures without airflow exposure (white bars; forskolin three lungs, n = 21; albuterol one lung, n = 8). b Representative tracings of FRET
ratios over time as a reflection of changes in [cAMP]i upon stimulation with forskolin in the presence (red) and absence (black) of roflumilast.
c Smoke exposed cells (black bar) show a decreased baseline FRET ratio compared to cultures exposed to airflow (grey bar), possibly indicating a
decreased intracellular cAMP level (three different lungs, n = 30). However, FRET ratios under these conditions cannot be calibrated to [cAMP]i.
d Roflumilast leads to a significant increase in the forskolin-induced ΔFRET ratio in air control (gray) and smoke exposed (black) cultures using the
Vitrocell VC-10 smoke exposure system (three different lungs, n = 21–43). e Roflumilast treated cultures show a prolonged elevation of the FRET
ratio after washout of forskolin in air control and smoke exposed cells (three different lungs, n = 21–43). *p < 0.05
Schmid et al. Respiratory Research  (2015) 16:135 Page 4 of 11
was reduced by cigarette smoke. On the other hand, roflu-
milast still significantly prolonged the increase in [cAMP]i
in smoked cells after forskolin washout.
Effect of roflumilast on apical chloride conductance
The effect of roflumilast on apical chloride conductance
was measured by short circuit currents (Isc) in NHBE
cells. Adding 100 nM roflumilast alone (Fig. 2a) resulted
in a minimal current change of 0.99 ± 0.22 μA/cm2
(14 lungs, n = 29), which was significantly less than the
changes observed after apical addition of 10 μM albute-
rol (11.75 ± 2.62 μA/cm2, p < 0.05). Use of a chloride-
free apical solution did not enhance the effect of roflu-
milast (not shown).
Pretreatment with roflumilast significantly increased
the response to albuterol (19.02 ± 2.27 μA/cm2; p < 0.05).
The dynamics of chloride conductance in cultures
treated with roflumilast, albuterol and their combination
is demonstrated in Fig. 2b. Effects of 100 nM roflumilast
on cultures exposed to control airflow or cigarette
smoke in the Vitrocell VC-10 smoking robot are shown
in Fig. 2c. Roflumilast increased the short circuit current
response to albuterol in air-exposed control cells (6.69 ±
1.14 μA/cm2 vs 4.8 ± 0.71 μA/cm2; p < 0.05). Smoke ex-
posure significantly decreased chloride conductance
compared to controls (2.1 ± 0.26 μA/cm2 vs 4.8 ±
0.71 μA/cm2; p < 0.05) but roflumilast reversed the
smoke effect (5.26 ± 0.65 μA/cm2 vs 2.1 ± 0.26 μA/cm2;
p < 0.05) so that changes in Isc in roflumilast-treated,
smoked-exposed cultures were similar to untreated air-
flow controls (5.26 ± 0.65 μA/cm2 vs 4.8 ± 0.71 μA/cm2;
p > 0.05). As shown in Fig. 2d, DMSO did have no effect
on chloride conductance in air control (9.4 ± 1.5 μA/cm2
vs 8.9 ± 2.3 μA/cm2) and cigarette smoke exposed cells
(4.1 ± 0.6 μA/cm2 vs 3.9 ± 0.4 μA/cm2: 2 different lungs,
n = 4).
These data show that roflumilast increased albuterol-
stimulated apical chloride efflux and rescued the nega-
tive effect of cigarette smoke on this conductance.
Addition of roflumilast without additional stimulation
with albuterol or forskolin increased Isc only minimally.
Effect of roflumilast on CFTR function in smoke-exposed
cells
To assure that the observed effects of roflumilast on Isc
were truly related to Cl− efflux via CFTR, smoke- or air-
exposed ALI cultures were pretreated basolaterally with
100 nM roflumilast, mounted in Ussing chambers, stim-
ulated with 10 μM albuterol and then 10 μM CFTR an-
tagonist CFTRinh172 was added apically (Fig. 3a). The
observed decrease in Isc is a more specific measure of
CFTR activity. Roflumilast increased CFTR-dependent
Cl− secretion in air-exposed cells (−6.74 ± 1.79 μA/cm2
vs −4.81 ± 1.29 μA/cm2; p < 0.05, n = 19). Smoke expos-
ure decreased CFTR conductance compared to air con-
trol (−2.26 ± 0.51 μA/cm2 vs −4.51 ± 1.29 μA/cm2;
p < 0.05) and roflumilast improved CFTR function in
smoked cells to a level similar to controls (−3.54 ±
1.00 μA/cm2 vs −4.51 ± 1.29 μA/cm2; p < 0.05; Fig. 3a).
The ratio of CFTR conductance in response to albuterol
in the absence and presence of roflumilast was not sta-
tistically different between smoke- and air-exposed con-
trol cells (1.34 ± 0.19 vs 1.9 ± 0,37; p > 0.05; Fig. 3b).
These data show that roflumilast enhanced impaired
CFTR function in NHBE cell cultures exposed to
cigarette smoke.
Fig. 2 Effect of roflumilast on apical chloride conductance with and without smoke exposure. a Evaluation of chloride conductance in control
cultures without airflow exposure (white bars): Application of roflumilast (100 nM) alone induces a minimal increase in Isc (14 lungs, n = 29).
Albuterol (10 μM) induces an increase in peak chloride efflux (ΔIsc) that is augmented by pre-treatment with roflumilast (100 nM) (six to ten lungs;
n = 6–10). b Representative tracing of an Ussing chamber experiment demonstrates an increase of chloride efflux after administration of 10 μM of
albuterol (black). Application of roflumilast alone hardly increases the conductance, whereas the addition of albuterol to roflumilast (red) treated
cultures significantly increases chloride conductance compared to untreated cultures. c Chloride efflux is significantly decreased in cultures
exposed to cigarette smoke (black bars) using the Vitrocell VC-10 smoking robot when compared to air control (grey bars). Roflumilast significantly
increases apical chloride efflux in air-exposed cells and rescues smoke-associated decreases in chloride conductance (19 lungs; n = 19). d Control
experiments, DMSO (vehicle) does not show any changes in the response of chloride conductance to albuterol in air and cigarette
smoke-exposed cultures (two lungs; n = 4). *p < 0.05
Schmid et al. Respiratory Research  (2015) 16:135 Page 5 of 11
Effect of roflumilast on Airway Surface Liquid (ASL)
To measure airway surface liquid (ASL) volume, a previ-
ously described meniscus scanning method [20] was
used as outlined in methods. A good correlation of mea-
sured volumes with the meniscus scanning method was
found when measuring 30 min and 3 h after addition of
5, 10 and 20 μl PBS to control cells (Fig. 4a). ASL mea-
surements were taken at different time points after
smoke or air exposure (Fig. 4b and c). Baseline measure-
ments were taken 1 h after exposure, just prior to roflu-
milast addition (100 nM; all n = 6). Measurements of
ASL were done after 4, 7, and 24 h of smoke/air expos-
ure. While air-exposed cells increased ASL over time
after exposure to reach baseline again after 24 h, smoke-
exposed cells revealed a blunted response with a de-
crease of ASL that trended to fall below baseline after
24 h (however this did not reach statistical significance).
Roflumilast enhanced ASL volume increases in both air-
and smoke-exposed cells (Fig. 4b and c). At 24 h, the
roflumilast treated, smoke exposed cells had an ASL vol-
ume that was significantly higher than the control cells
that were only smoke exposed.
These data show that roflumilast enhances ASL vol-
ume in NHBE cell cultures and partially reverses the
negative effect of cigarette smoke.
Ciliary Beat Frequency (CBF)
To examine the effect of roflumilast on smoke-mediated
changes in CBF, fully differentiated NHBE cells were
used after basolateral treatment with 100 nM roflumi-
last. DMSO controls were published by us before:
DMSO did not show any significant effects on CBF [13].
Fig. 3 Effect of roflumilast on CFTR function. a Basolateral pretreatment of cells exposed to either air flow (air control; grey bars) or cigarette
smoke (black bars) with 100 nM roflumilast improves CFTR function as measured by the decrease in Isc after apical application of 10 μM
CFTRinh172; all cells were stimulated with 10 μM albuterol prior to CFTR inhibition. Roflumilast rescues CFTR function in smoke exposed cells to a
level not different to the untreated air exposed cells. b Air and cigarette smoke exposed cultures show similar fold increases in CFTR conductance
with and without roflumilast (19 lungs; n = 19). * p < 0.05
Fig. 4 Effect of roflumilast on Airway Surface Liquid (ASL). a Calibration of ASL measurements shows a good correlation between added and
measured Δ volumes in 12 mm Corning Transwell filters measured 30 min after addition (n = 7). Similar results were found when measuring after
3 h (not shown). b Following ASL volumes over time after exposure to air shows an initial increase in ASL volume that returns to baseline after
24 h. Roflumilast enhances the response and keeps ASL above baseline at the 24 h time point (six different lungs, n = 6, # p < 0.05 for comparison
between control and roflumilast treated cells at different time points). c Following ASL volumes over time after exposure to cigarette smoke
shows a blunted initial increase. Roflumilast on the other hand, increases initial volume and restores the ASL volume response after smoke
exposure, comparable to air exposure, keeping the ASL volume close to baseline at 24 h (six different lungs, n = 6, # p < 0.05 for comparison
between control and roflumilast treated cells at different time points). Black and red dotted line in B/C for comparison of baseline of control
(black) and roflumilast treated (red) cultures. d Control experiments with DMSO as vehicle do not show any difference in Δ ASL measurements
between 1 and 4 h in air versus cigarette smoke exposed cultures (two lungs; n = 4). * p < 0.05
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Baseline measurements were made one hour after roflu-
milast addition, before the cells were exposed to
cigarette smoke or air in the Vitrocell VC-10 robot (con-
trol). Three hours after smoke/air exposure (four hours
after treatment with roflumilast), CBF was measured.
Baseline CBF of the cultures was 4.5 ± 0.2 Hz before and
4.68 ± 0.2 Hz 1 h after exposure to 100 nM roflumilast
(p > 0.05; five lungs, n > 14). Exposure of the cultures to
airflow (air control) did not change CBF in untreated
cells. However, airflow increased CBF significantly when
pre-treated with roflumilast for 4 h (4.19 ± 0.25 Hz vs.
6.63 ± 0.5 Hz; p < 0.05). Three hours after exposure to
cigarette smoke, CBF decreased compared to air control
(1.28 ± 0.06 Hz vs 4.19 ± 0.24 Hz; n > 14 each; p < 0.05)
and non-exposed cultures (4.5 ± 0.2 Hz). Roflumilast in-
creased CBF of the smoke-exposed cells significantly at
3 h (3.31 ± 0.43 Hz vs 1.28 ± 0.06 Hz; p < 0.05) and CBF
of roflumilast treated, smoke-exposed cultures was not
different compared to air-control cultures (3.31 ±
0.43 Hz vs 4.19 ± 0.24 Hz, p > 0.05). After initial CBF
measurements, 50 μl PBS was added apically to replen-
ish ASL volume. This maneuver equalized CBF in air-
and smoke-exposed cells with or without roflumilast
(5.78 ± 0.54 Hz vs 6.67 ± 0.22 Hz vs 6.04 ± 0.3 Hz vs
6.82 ± 0.37 Hz; p > 0.05 for all comparisons; Fig. 5a), pos-
sibly indicating ASL volume loss as the main reason for
the CBF decrease rather than a direct smoke effect on
cilia. However, a lower [cAMP] after smoke exposure
may contribute here as well.
To evaluate the effect of roflumilast on CBF independ-
ent of ASL volume, we measured CBF in submerged
conditions. Treatment with 10 μM forskolin increased
CBF in air control cells in the absence and presence of
roflumilast (8.75 ± 0.5 Hz vs 10.15 ± 0.55 Hz and 8.73 ±
0.6 Hz vs 10.9 ± 0.62 Hz respectively; n > 10; p < 0.05;
Fig. 5b). Similar changes were seen in smoke-exposed
cells and smoke-exposed cells treated with roflumilast
(4.48 ± 0.31 Hz vs 5.69 ± 0.33 Hz and 5.29 ± 0.25 Hz vs
7.29 ± 0.29 Hz respectively; p < 0.05). CBF of smoke-
exposed cells treated with roflumilast and forskolin had
a higher CBF than cells treated only with forskolin (7.29
± 0.29 Hz vs 5.69 ± 0.33 Hz; p < 0.05). This indicates that
roflumilast had a stimulatory effect on smoke-exposed
cilia directly, independent of ASL volume changes. How-
ever, the same phenomenon was not observed in air
control cells.
The increased baseline of CBF in these submerged ex-
periments compared to the other CBF measurements
after apical PBS addition may be related to the fact that
the evaluations were done with constant fluid flow in
the apical compartment that may stimulate CBF. These
data suggest that the CBF changes in Fig. 5b are not re-
lated to ASL volume changes, but rather to an increase
in cAMP production (see Fig. 1) directly affecting CBF.
In summary, roflumilast has a dual effect on CBF: it
directly reverses smoke-induced CBF decreases and in-
creases smoke-related reductions in ASL volume,
thereby indirectly allowing normal ciliary beating. The
smoke-induced lower CBF baselines in Fig. 5a and b
may be due to the lower baseline cAMP levels after
smoke exposure suggested by the FRET experiments dis-
cussed above.
Fig. 5 Effect of roflumilast on ciliary beat frequency (CBF). a CBF measurement after roflumilast exposure for 4 h (baseline in white bars on the
left of the graph after 1 h; five lungs; n = 14–40). Roflumilast-treated cultures did not show an increase in CBF compared to untreated cultures
(baseline). Smoke (4 h after roflumilast) significantly decreases CBF 3 h after exposure, an effect reversed by roflumilast. Exposure to air (air control)
increases CBF upon administration of roflumilast (gray bars). Bars on a blue background indicate measurements of CBF after rehydration of the
apical surface with 50 μl PBS. CBF of cells exposed to smoke vs air equalizes, indicating a role of ASL volume depletion in the CBF changes
(* p < 0.05). b CBF measurements after short-term exposure of roflumilast for 15 min followed by addition of 10 μM forskolin in a submerged,
two chamber perfusion system (three lungs; n = 10-14). In air control cultures, forskolin increases CBF, but the addition of roflumilast does not
further enhance CBF. In smoke-exposed cells, CBF increases upon forskolin addition, and again with roflumilast. CBF baselines are low in
smoke-exposed cells, possibly correlating to the lower baseline cAMP levels in smoke exposed cells as assessed by FRET (taken at the same time
points). * p < 0.05
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Effects of the long acting ß2 adrenergic agonist
formoterol with roflumilast
All experiments so far described results using forskolin
or the short acting ß2 mimetic albuterol to increase
cAMP levels. In clinical practice, long acting ß2 adrener-
gic agonists are used for chronic treatment of COPD,
whereas short acting ß2 agonists are employed as rescue
inhalers for symptomatic relief [21]. Based on this fact,
we examined the effect of formoterol on CFTR and CBF
in the absence and presence of roflumilast in control
and smoke exposed cultures.
Figure 6a shows specific CFTR conductance evaluated
by Isc decreases upon channel inhibition with
CFTRinh172 in the acute presence of 10 μM albuterol in
addition to the experimental conditions. Cultures were
incubated with 100 mM roflumilast, 100 nM formoterol,
both or none for 2 h before adding 10 μM of albuterol.
Specific CFTR conductance was significantly decreased
in cigarette smoke exposed compared to control cultures
(−3 ± 0.79 vs −6.9 ± 1.99 μA/cm2). Roflumilast alone did
not significantly improve CFTR function either in
smoked (−4.58 ± 1.67 μA/cm2) or in control cultures
(−9.6 ± 2.8 μA). Formoterol alone, however, improved
CFTR function (−6.37 ± 1.2 μA/cm2 and −12.6 ± 2.3 μA/
cm2 respectively; 11 lungs, n = 11). Next, we evaluated
the effect of the combination of formoterol and roflumi-
last on CBF (Fig. 6b). As expected, CBF was decreased
in cigarette smoke exposed versus control cells (2.5 ±
0.7 Hz vs 8.2 ± 0.6 Hz; n = 11; p < 0.05). Neither roflumi-
last nor formoterol alone improved CBF. However, the
combination of the both significantly increased CBF in
smoked cells to a level similar to control cultures (7.9 ±
0.6 vs 7.9 ± 0.6 Hz; 11 lungs, n = 11).
CFTR expression in cells brushed from patients
We examined the effect of cigarette smoke and
roflumilast on CFTR mRNA expression in airway
epithelia cells (Fig. 7). First, qPCR was performed on
cells from bronchial brushes obtained during bron-
choscopies of individuals with different smoking his-
tories (Fig. 7a). The groups were patients that never
smoked, current smokers (at least 10 pack years),
and ex-smokers (quit smoking at least 1 year before
collection of the cells). We found that current
smokers had a significant increase in CFTR expres-
sion compared to non-smokers and ex-smokers
(44.5 ± 8.1 vs 16.4 ± 2.3 vs 15.3 ± 2.1; expression rela-
tive to GAPDH * 1000; each n > 12; p < 0.05). CFTR
expression in ex-smokers returned to the level of
non-smokers (p > 0.05).
CFTR expression in cultured airway epithelial cells
from non-smokers (Fig. 7b) did not increase acutely after
exposure to cigarette smoke (four cigarettes) compared
to air control (0.89 ± 0.2 vs 0.88 ± 0.1; p > 0.05). When
air control cultures were treated with 100 nM roflumi-
last, there was also no significant change in CFTR ex-
pression (0.88 ± 0.1 vs 1.08 ± 0.1; n = 12; p > 0.05).
However, when cells from non-smokers, exposed to
smoke were treated with roflumilast, an increase in
CFTR expression was observed (0.88 ± 0.18 vs 1.45 ± 0.2;
p < 0.05).
Fig. 6 Effect of long acting ß2 mimetic in combination with roflumilast on CFTR function and ciliary beat frequency (CBF). a CFTR function,
assessed by adding 10 μM albuterol followed by CFTRinh172, shows a significant decrease in cigarette smoke-exposed cell cultures compared to
air control conditions. CFTR function remains significantly lower in smoke exposed cells compared to air controls when adding roflumilast,
formoterol or both. Treatment with formoterol improves CFTR function in both smoke and air control compared to non-treated cells, whereas
treatment with roflumilast alone under the same conditions does not. b CBF is decreased in smoke exposed cells compared to air controls.
Neither roflumilast nor formoterol alone rescue smoke-induced decreases in CBF. However, the combination of both restores CBF levels to air
control. * for p < 0.05, 11 lungs with n = 11 for all experiments
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Discussion
Our results show that inhibition of PDE4 with roflumi-
last improves parameters of mucociliary clearance in
NHBE cells. It increases ASL volume by enhancing ap-
ical chloride efflux through CFTR. It also stimulates
CBF via an indirect effect on ASL volume and a direct
effect on cilia. These changes reverse some of the nega-
tive effects of cigarette smoke on MCC and provide fur-
ther mechanistic evidence that may explain the
beneficial effects of this drug on reducing COPD
exacerbations.
Following observations that PDE4 inhibition in ro-
dents reduced tobacco smoke-mediated neutrophil in-
flux in BAL, reduced lung parenchyma infiltration of
neutrophils, macrophages and lymphocytes, and inhib-
ited endothelial-neutrophil cell interactions [22, 23], ini-
tial studies of roflumilast in populations with COPD
focused on its anti-inflammatory effects. Roflumilast has
been found to reduce sputum neutrophils, eosinophils,
and soluble markers of neutrophilic and eosinophilic in-
flammation compared with placebo [24]. It also de-
creases other inflammatory molecules such as
metalloproteinases and TGF-ß [25–27]. Clinically, this
translates not only in a decrease in the rate of mild to
moderate exacerbations and a prolongation of the time
to the next exacerbation, but also into improved spiro-
metric values and patient-oriented outcomes such as im-
provements in dyspnea scores [28, 29].
MCC is a key mechanism to protect the airways from
inhaled particles and infectious agents. Major compo-
nents of this apparatus include: 1) effectively beating
cilia that move mucus out of the airways and 2) an ad-
equate ASL volume allowing cilia to beat efficiently and
hydrating mucus optimally. If MCC fails, patients can
develop chronic bronchitis, COPD, bronchiectasis and
are prone to pulmonary infections [30]. Our studies may
provide some understanding on basic non-inflammatory
related mechanisms as to why roflumilast positively
influences COPD in patients, namely its effects on ASL
volume and ciliary beating.
In our Ussing chamber experiments, 100 nM roflumi-
last alone did not increase Isc (Fig. 2a). Since phospho-
diesterase inhibitors do not directly increase [cAMP]i,
but decrease its break down, this finding is not surpris-
ing, at least for an acute situation. Chronically, it’s pos-
sible that roflumilast can elevate cAMP through
intrinsic activities of adenylyl cyclases via some basic
stimulation by adenosine for instance. This theory is
supported by our findings that roflumilast did not
change baseline CBF in control cells, but increased it in
cells exposed to control airflow (Fig. 5a). Airflow in-
creases ATP release through pannexins [31] and the
resulting adenosine increase could stimulate adenylyl cy-
clase [32], allowing roflumilast to have a significant
effect.
In contradiction to our findings, Lambert et al. pub-
lished a study where the sole addition of 1 nM roflu-
milast increased Isc close to 10 μA/cm
2 [33].
Additionally, roflumilast had an EC50 of 2.9 nM with
a maximal effect of about 40 μA/cm2. In order to
achieve these high responses with such doses of roflu-
milast, the authors highlighted the use of a low extra-
cellular chloride concentration (higher driving force).
We repeated these experiments but did not observe
the Isc stimulations described by Lambert. In addition
and in contrast to these authors, we saw a significant
effect of 10 μM forskolin addition on Isc after expos-
ure to roflumilast. It is unclear why similar experi-
ments can lead to such different results. One possible
explanation is that we used fully differentiated NHBE
cells whereas the cited study used primary bronchial
epithelial cells grown in submerged monolayers or
Calu3 cells. In addition, others have published in-
creases in CBF with sole addition of roflumilast N-
oxide [34], an effect only seen upon smoke exposure
in our culture system.
Fig. 7 Change in CFTR expression in brushed cells obtained during bronchoscopies and NHBE cultures. a Expression of CFTR is increased in
brushed cells obtained from airways of smokers compared to non-smokers and ex-smokers. (four to six lungs, n = 12–18). b In cultured epithelial
cells from non-smokers, acute exposure to cigarette smoke does not change CFTR expression compared to control air-exposed cells within 3 h of
exposure. Roflumilast (red framed boxes) appears to increase CFTR expression in the smoke-exposed cells after 3 h (four lungs, n = 12) *
for p < 0.05
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Our study showed beneficial effects of roflumilast on
NHBE cells exposed to cigarette smoke. Interestingly,
smoke did not decrease [cAMP]i responses as measured
by FRET, even though it might lower baseline [cAMP],
consistent with smoke-induced decreases in CFTR func-
tion and ASL volume. Baseline FRET measurements,
cannot be calibrated, and therefore these results have to
be interpreted with caution. On the other hand, roflumi-
last rescued decreased apical CFTR conductance and
ASL volume by simultaneously increasing [cAMP]i. A
decrease of cAMP in cigarette smoke extract has previ-
ously also been described in bronchial fibroblasts [35].
It has already been known that cigarette smoke re-
duces CFTR function [7–9] and that this negative effect
can be rescued by roflumilast [33]. However, our study
goes further by demonstrating that the roflumilast-
induced improvement of CFTR function leads to a res-
cue of ASL volume and a complex improvement of CBF
(direct and indirect effect via ASL volume) as well.
The effect of the [cAMP]i on CBF has been well docu-
mented in mammals [36–38]. Here we show that CBF
increases more than 50 % in smoke-exposed cells in the
presence of roflumilast and an additional 25 % after
addition of forskolin. Roflumilast also increased CBF by
about 50 % in air-exposed cultures. This finding is excit-
ing as the control cultures exposed to airflow represent
the airway epithelium in non-smoking individuals simu-
lating air movements during inhalation and exhalation.
Furthermore, formoterol, a long acting ß2-adrenergic
agonist and cornerstone of the treatment of symptom-
atic COPD [21], enhanced roflumilast’s ability to stimu-
late CBF in cigarette smoke exposed cells as shown in
Fig. 6b.
While alterations in one parameter of mucociliary
clearance not always translate into a complementary
change of all parameters, it has been shown that a 16 %
change in CBF can be associated with a 56 % improve-
ment in mucociliary clearance [39]. Thus, the observed
differences with respect to CBF could translate into sig-
nificant improvements of mucociliary clearance.
Our data contain some unexpected findings. The
ASL volume increased initially upon smoke exposure,
likely due to mucus secretion. Those initial changes
were not necessarily reflected in CBF, indicating that
additional mechanisms must be at work that could
include surface viscosity. We also showed that air-
way epithelial cell CFTR mRNA expression is in-
creased in subjects who were active smokers.
However, CFTR function and protein expression
have been shown to be depressed not only here but
also in patients who actively smoke [40]. Thus,
mRNA levels of CFTR are not good predictors of
the channel’s apical function. Our results show a de-
creased expression of CFTR in ALI cultures
compared to brushes from airways, a finding that
has been previously reported [41].
The pathophysiology of COPD is complex. Tobacco
smoke induces many anatomical changes including
mucus cell hyperplasia and a lower number of ciliated
cells with shortened cilia [42] as well as peri-bronchiolar
fibrotic changes. Besides its effects on inflammatory
cells, PDE-4 inhibition has been shown to decrease
EGF-induced MUC5AC expression in human airway
epithelial cells [43], to reduce airway mucous metaplasia
via its anti-inflammatory properties [44], and to exhibit
antifibrotic effects by targeting fibroblasts [45]. Together,
these observations along with our findings of additional
positive effects on smoke-induced impairment of MCC,
provide a more comprehensive mechanistic understand-
ing of the beneficial effects of roflumilast in COPD, in
particular for those with chronic bronchitis. While the
effect of roflumilast seems clear for improving ciliary
function, we do not suggest that this is the only way
roflumilast might be beneficial. The effect on ASL vol-
ume will affect also mucus hydration and the two effects
together will likely have the most significant effect in
disease.
Conclusion
Our results show that roflumilast increases ASL volume
and CBF in fully differentiated NHBE cells exposed to
smoke by increasing [cAMP]i and in part, by enhancing
apical chloride efflux via CFTR.
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